Your browser doesn't support javascript.
loading
Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer.
Huang, Yan; Hu, Wei; Huang, Jie; Shen, Fangrong; Sun, Yunjie; Ivan, Cristina; Pradeep, Sunila; Dood, Robert; Haemmerle, Monika; Jiang, Dahai; Mangala, Lingegowda S; Noh, Kyunghee; Hansen, Jean M; Dalton, Heather J; Previs, Rebecca A; Nagaraja, Archana S; McGuire, Michael; Jennings, Nicholas B; Broaddus, Russell; Coleman, Robert L; Sood, Anil K.
Afiliação
  • Huang Y; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Hu W; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Huang J; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Shen F; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Sun Y; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ivan C; Center for RNA Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Pradeep S; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Dood R; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Haemmerle M; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Jiang D; Center for RNA Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Mangala LS; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Noh K; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Hansen JM; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Dalton HJ; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Previs RA; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Nagaraja AS; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • McGuire M; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Jennings NB; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Broaddus R; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Coleman RL; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Sood AK; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. asood@mdanderson.org.
Mol Cancer Ther ; 17(2): 464-473, 2018 02.
Article em En | MEDLINE | ID: mdl-29237804
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Uterinas / Receptores de Progesterona / Gonanos / Antineoplásicos Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Uterinas / Receptores de Progesterona / Gonanos / Antineoplásicos Idioma: En Ano de publicação: 2018 Tipo de documento: Article